Daily Sepsis Research Analysis
Analyzed 13 papers and selected 3 impactful papers.
Summary
Three impactful sepsis studies span clinical prediction in resource-limited pediatrics, mechanistic metabolic rescue of sepsis-associated acute kidney injury, and a multifunctional nanotherapy for sepsis-related encephalopathy. Collectively, they advance risk stratification and propose novel therapeutic avenues targeting mitochondrial bioenergetics and combined antioxidant/antimicrobial strategies.
Research Themes
- Point-of-care biomarker-driven risk stratification in pediatric sepsis
- Mitochondrial bioenergetics and AMPK-mTOR-SIRT3 signaling in sepsis-associated organ injury
- Multifunctional nanotherapeutics for sepsis-related encephalopathy
Selected Articles
1. Predicting Mortality in Tanzanian Children With Sepsis Using Point-of-Care Biomarkers.
In a prospective cohort of 755 Tanzanian children with sepsis, procalcitonin and simple clinical features (malnutrition, breathing difficulty, altered mental status) predicted in-hospital mortality with high accuracy (AUC 0.87). The combined POC biomarker-clinical model outperformed individual components.
Impact: Provides a practical, high-performing mortality prediction tool tailored for resource-limited settings using POC biomarkers plus basic clinical signs.
Clinical Implications: Supports integrating PCT-based POC testing with simple clinical assessments to triage pediatric sepsis, prioritize monitoring, and allocate scarce resources effectively in RLS.
Key Findings
- Among 755 children with sepsis, in-hospital mortality was 19.6% (n=148).
- Procalcitonin and selected clinical features were each significantly associated with mortality (all p<0.001).
- A multivariable model (PCT, malnutrition, breathing difficulty, altered mental status) achieved AUC 0.87 (95% CI 0.84-0.90), outperforming individual biomarkers or signs.
Methodological Strengths
- Prospective observational cohort with predefined POC biomarkers and standardized data collection
- Use of LASSO regression and AUC with confidence intervals to assess model performance
Limitations
- Single-center study in Dar es Salaam may limit generalizability to other RLS
- Observational design without external validation limits causal inference and transportability
Future Directions: External, multicenter validation and impact evaluation trials to test real-world implementation and clinical decision support integration.
BACKGROUND AND OBJECTIVES: Sepsis is a leading cause of child mortality worldwide, disproportionately affecting children in resource-limited settings (RLS). Effective risk-stratification tools using readily available data are urgently needed for this population. Therefore, the study objective was to evaluate the performance of point-of-care (POC) biomarkers and clinical characteristics for predicting in-hospital mortality among Tanzanian children with sepsis. METHODS: We conducted a prospective observational cohort study of children (28 days-14 years) with sepsis presenting to Muhimbili National Hospital in Dar es Salaam, Tanzania (July 2022-November 2024). POC biomarkers (procalcitonin [PCT], C-reactive protein, ferritin, and lactate) and clinical characteristics were evaluated for their association with mortality. We used the least absolute shrinkage and selection operator (LASSO) regression to construct predictive models of mortality. We evaluated model performance using the area under the receiver operating characteristic curve (AUC) and classification metrics, including sensitivity and specificity. RESULTS: Among the 755 enrolled participants, 19.6% (n = 148) died during hospitalization. PCT and tested clinical characteristics were significantly associated with mortality (all p<0.001). A multivariable model incorporating PCT, malnutrition, breathing difficulty, and altered mental status demonstrated strong discrimination (AUC 0.87, 95% CI 0.84-0.90), outperforming individual biomarkers and clinical characteristics alone. CONCLUSIONS: A combined POC biomarker and clinical characteristics model was highly predictive of mortality among children with sepsis in Tanzania. Integrating POC biomarkers with easy-to-measure clinical characteristics associated with severity may enable timely risk stratification and inform targeted interventions to improve pediatric sepsis outcomes in RLS.
2. Exogenous pyruvate restores mitochondrial bioenergetics by synergizing with the AMPK-mTOR-SIRT3 pathway to alleviate sepsis-associated acute kidney injury.
In CLP-induced SA-AKI mice and LPS-stimulated HK-2 cells, ethyl pyruvate synergized with AMPK activation (AICAR) to improve renal function, reduce injury and inflammation, and increase survival. scRNA-seq revealed sepsis-driven mitochondrial dysfunction and OXPHOS suppression; combined EP+AICAR restored mitochondrial bioenergetics via the AMPK-mTOR-SIRT3 axis.
Impact: Identifies a metabolically targeted, mechanistically grounded strategy to rescue mitochondrial function in SA-AKI, supported by multi-system validation including scRNA-seq.
Clinical Implications: Supports development of adjunct metabolic therapies (e.g., pyruvate donors and AMPK activators) for SA-AKI; provides mechanistic rationale for early-phase clinical trials.
Key Findings
- Ethyl pyruvate synergized with AMPK activator AICAR to improve renal function and survival in CLP-induced SA-AKI.
- scRNA-seq identified mitochondrial dysfunction and OXPHOS suppression in renal epithelial cells during sepsis.
- Combined EP+AICAR, rather than EP alone, restored mitochondrial bioenergetics via the AMPK-mTOR-SIRT3 pathway.
Methodological Strengths
- Integrated in vivo (CLP mouse) and in vitro (LPS-stimulated HK-2) models
- Single-cell RNA sequencing to map cell-type specific metabolic reprogramming
Limitations
- Preclinical study; translatability to humans remains to be established
- Dosing, timing, and long-term safety/efficacy parameters are not defined in the abstract
Future Directions: Optimize dosing and timing, evaluate in large-animal sepsis models, and design early-phase clinical trials focusing on mitochondrial endpoints.
Sepsis-associated acute kidney injury (SA-AKI) is closely linked to profound metabolic reprogramming and mitochondrial dysfunction, yet effective metabolic targeted therapies remain limited. In this study, we elucidated the molecular mechanism by which ethyl pyruvate (EP), an exogenous metabolic substrate, alleviates SA-AKI by regulating mitochondrial bioenergetics through the AMPK-mTOR-SIRT3 signaling pathway. Using a cecal ligation and puncture-induced SA-AKI mouse model and LPS-stimulated HK-2 cells, we demonstrated that EP synergized with the AMPK activator AICAR to significantly improve renal function, reduce injury markers and inflammation, and enhance survival. Single-cell RNA sequencing (scRNA-seq) identified extensive metabolic reprogramming in renal epithelial cells during sepsis, characterized by mitochondrial dysfunction and suppression of oxidative phosphorylation (OXPHOS). Mechanistically, combined EP and AICAR treatment, rather than EP alone, alleviated mitochondrial dysfunction by restoring NAD
3. Buforin IIb and bilirubin co-loaded CeO₂ nanoparticles mitigate sepsis-related encephalopathy via synergistic anti-inflammation and neuroprotection.
A cerium-oxide nanoparticle platform co-delivering buforin IIb and bilirubin provided combined antioxidant, anti-inflammatory, and antimicrobial actions to ameliorate sepsis-related encephalopathy in preclinical models. The multifunctional design targets key pathophysiologic axes simultaneously.
Impact: Introduces a single nanoplatform that addresses oxidative stress, inflammation, and infection concurrently—an innovative approach to a multifactorial sepsis complication.
Clinical Implications: While preclinical, the approach suggests potential to reduce neuroinflammation and neuronal injury in sepsis-related encephalopathy; it may inform future translational nanomedicine strategies.
Key Findings
- Developed cerium-based nanomodulators (CBB NPs) co-loaded with buforin IIb and bilirubin.
- Achieved synergistic antioxidant, anti-inflammatory, and antimicrobial effects in sepsis models.
- Demonstrated mitigation of sepsis-related encephalopathy, indicating neuroprotection.
Methodological Strengths
- Rational multifunctional nanoplatform integrating catalytic antioxidant core with therapeutic payloads
- Targeting of multiple sepsis pathophysiologic mechanisms within a single delivery system
Limitations
- Preclinical data; safety, biodistribution, and scalability in humans remain unknown
- Detailed in vivo efficacy metrics and long-term outcomes are not described in the abstract
Future Directions: Assess pharmacokinetics, safety, and efficacy in larger animal models; optimize dosing and explore combination with standard sepsis care.
Sepsis, a dysregulated host response to infection causing life-threatening organ dysfunction, remains a leading cause of mortality worldwide with death rates exceeding 30%. Current therapeutic approaches inadequately address the complex pathophysiology involving uncontrolled cytokine release, oxidative stress, and persistent infection. Here we report cerium-based nanomodulators (CBB NPs) that integrate antioxidant, anti-inflammatory, and antimicrobial functions for synergistic therapy. The nanoplatform comprises hollow mesoporous cerium oxide nanoparticles (CeO₂ NPs) as catalytic cores, exploiting Ce